Safety, Pharmacodynamic, and Antitumor Activity of Tidutamab, an SSTR2 x CD3 Bispecific Antibody, in Subjects With Advanced Neuroendocrine Tumors El-Rayes, B. F., Hendifar, A. E., Pant, S., Wilky, B. A., Reilley, M. J., Benson, A. B., Chow, W. A., Konda, B., Starr, J., Ahn, D. H., Kunz, P. L., Strosberg, J. R., Eads, J. R., Perez, K. J., Raj, N. P., Fisher, G. A., Chollate, S., Fleener, C. A., Ding, Y., Tang, Z. LIPPINCOTT WILLIAMS & WILKINS. 2022: E58

View details for Web of Science ID 000819123700109